Lv2
170 积分 2024-08-27 加入
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma
1个月前
已完结
GPRC5D as a novel immunotherapeutic target in multiple myeloma
1个月前
已完结
Talquetamab: First Approval
1个月前
已完结
GPRC5D-CAR T cells active in MM
1个月前
已完结
Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
1个月前
已完结
GPRC5D-Targeted CAR T Cells for Myeloma
1个月前
已完结
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
1个月前
已完结
GPRC5D-Targeted CAR T Cells for Myeloma
1个月前
已完结
T-cell-engaging bispecific antibodies in cancer
1个月前
已完结
GPRC5D-targeted bispecific bolsters T-cell-engager pipeline
1个月前
已完结
皖公网安备34019202002308
